OncoMatch/Clinical Trials/NCT06966388
Study to Evaluate the Feasibility of Twice Daily Use of Topical Azelaic Acid in Breast Cancer Patients Undergoing Radiation
Is NCT06966388 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Azelaic Acid for breast cancer.
Treatment: Azelaic Acid — This pilot study will evaluate the feasibility of at least twice daily use of azelaic acid in breast cancer patients undergoing radiation treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Virginia Commonwealth University · Richmond, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify